ES2107375B1 - LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY. - Google Patents

LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY.

Info

Publication number
ES2107375B1
ES2107375B1 ES9501556A ES9501556A ES2107375B1 ES 2107375 B1 ES2107375 B1 ES 2107375B1 ES 9501556 A ES9501556 A ES 9501556A ES 9501556 A ES9501556 A ES 9501556A ES 2107375 B1 ES2107375 B1 ES 2107375B1
Authority
ES
Spain
Prior art keywords
liquid pharmaceutical
pharmaceutical formulations
ebastin
oral way
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9501556A
Other languages
Spanish (es)
Other versions
ES2107375A1 (en
Inventor
Jose Luis Fabregas
Mauri Jacinto Moraques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to ES9501556A priority Critical patent/ES2107375B1/en
Publication of ES2107375A1 publication Critical patent/ES2107375A1/en
Application granted granted Critical
Publication of ES2107375B1 publication Critical patent/ES2107375B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULACIONES FARMACEUTICAS LIQUIDAS DE EBASTINA POR VIA ORAL. FORMULACIONES FARMACEUTICAS LIQUIDAS DE 4 -DIFENILMETOXI -1- [3- (4-TERBUTILBENZOIL) PROPIL] PIPERIDINA, CUYA DENOMINACION COMAN ES EBASTINA, QUE CONTIENEN ACIDOS CARBOXILICOS HIDROXILADOS, TENSIOACTIVOS NO IONICOS Y POLIOLES DE CADENA MEDIA EN UNA PROPORCION COMPRENDIDA ENTRE 1:1:3:25 Y 3:10:25:500 RESPECTIVAMENTE, JUNTO CON EXCIPIENTES O DILUYENTES FARMACEUTICAMENTE ACEPTABLES. ESTAS FORMULACIONES SE UTILIZAN PARA EL TRATAMIENTO DE PROCESOS ALERGICOS COMO RINITIS, URTICARIA, DERMATITIS O CONJUNTIVITIS.LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY. LIQUID PHARMACEUTICAL FORMULATIONS OF 4-DIPHENYLMETOXY -1- [3- (4-TERBUTILBENZOIL) PROPIL] PIPERIDINE, WHICH IS A DENOMINATION WHICH IS COMBINED BY EBASTINE, WHICH CONTAINS 1-CARBYLIC ACIDES, HYDROXYLATED TENSIOES : 3: 25 AND 3: 10: 25: 500 RESPECTIVELY, TOGETHER WITH PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS OR THINNERS. THESE FORMULATIONS ARE USED FOR THE TREATMENT OF ALLERGIC PROCESSES LIKE RHINITIS, URTICARIA, DERMATITIS OR CONJUNTIVITIS.

ES9501556A 1995-08-01 1995-08-01 LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY. Expired - Fee Related ES2107375B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9501556A ES2107375B1 (en) 1995-08-01 1995-08-01 LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9501556A ES2107375B1 (en) 1995-08-01 1995-08-01 LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY.

Publications (2)

Publication Number Publication Date
ES2107375A1 ES2107375A1 (en) 1997-11-16
ES2107375B1 true ES2107375B1 (en) 1998-07-01

Family

ID=8291245

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9501556A Expired - Fee Related ES2107375B1 (en) 1995-08-01 1995-08-01 LIQUID PHARMACEUTICAL FORMULATIONS OF EBASTIN BY ORAL WAY.

Country Status (1)

Country Link
ES (1) ES2107375B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013081562A1 (en) 2011-10-13 2013-06-06 Mahmut Bilgic Oral formulations comprising ebastine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2568473B1 (en) * 1984-08-03 1987-05-15 Vaillant Defresne Laboratoire NEW COMPOSITION BASED ON QUININE FORMIATE
FR2624736B1 (en) * 1987-12-16 1991-03-22 Dietlin Francois NEW WATER-DISPERSIBLE PHARMACEUTICAL COMPOSITIONS BASED ON ORNIDAZOLE
ZA90341B (en) * 1989-01-23 1990-10-31 Merrell Dow Pharma Liquid pharmaceutical composition for piperidinoalkanol derivatives
FR2673842B1 (en) * 1991-03-13 1993-12-24 Rhone Poulenc Rorer Sa NOVEL LIQUID COMPOSITIONS BASED ON 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES.
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form

Also Published As

Publication number Publication date
ES2107375A1 (en) 1997-11-16

Similar Documents

Publication Publication Date Title
NO971206D0 (en) Prolonged-frigjöringsformulering
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
CR9842A (en) CELECOXIB COMPOSITIONS
NO951613L (en) Non-peptidyl tachykinin receptor antagonists
AR008853A1 (en) NEW PHARMACEUTICALLY ACTIVE COMPOUNDS, THEIR USE IN THE MANUFACTURE OF MEDICINES, TREATMENT METHOD, PHARMACEUTICAL COMPOSITION, INTERMEDIATE COMPOUNDS AND PROCESS FOR THE MANUFACTURE OF SUCH COMPOUNDS
MA26901A1 (en) NEW PHARMACEUTICAL COMPOSITION
DE59509751D1 (en) AGING EFFECTS AGAINST SKIN AGING OR ACTIVE SUBSTANCE COMBINATIONS AND PREPARATIONS
AR018197A1 (en) PIPERIDINE COMPOUNDS, A PROCEDURE FOR THE PREPARATION, A COMPOSITION AND USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT
NO20051966L (en) New pyrimidinamide derivatives and their use
BR0215184A (en) orally active taxane derivative pharmaceutical compositions having increased bioavailability
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
NO961687D0 (en) New (R) -5-carbamoyl-8-fluoro-3-N, N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
AR043188A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF PROINFLAMATORY CYTOKINS
GT199800101A (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING A DERIVATIVE OF BENZOFURANE.
ES2192234T3 (en) PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING SALTS OF 2-ARILPROPIONIC ACIDS.
BR0013935A (en) Optically active isomers of ketotifen and therapeutically active metabolites thereof
SV2002000235A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE VALDECOXIB
DE59608698D1 (en) Pharmaceutical preparation for the treatment of acute rhinitis, containing sympthomimeticum and pantothenol and / or pantothenic acid
GT199700037A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RHINITIS
TR200400228T4 (en) Substances used in the treatment of psoriasis
CO5190674A1 (en) TREATMENT OF NEUROTIC DISORDERS NEUROTIC DISORDERS
RS50298B (en) Directly compressibile matrix for controlled release of single daily doses of clarithromycin
DK1274685T3 (en) A pyridine-N-oxide derivative and process for its conversion into pharmaceutically effective compounds
NO20000519L (en) 2-acylaminopropanamines as tachykinin receptor antagonists
ATE87468T1 (en) ANTACIDATE TABLETS.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19971116

Kind code of ref document: A1

Effective date: 19971116

PC2A Transfer of patent
FD2A Announcement of lapse in spain

Effective date: 20180806